Epilepsy caused by SCN2A variants mostly starts in early childhood and has a wide phenotypic spectrum, ranging from self-limited epilepsy with a favorable outcome to developmental and epileptic encephalopathy, and most of them respond well to sodium channel blockers (SCBs) (Grinton et al., 2015; Trump et al., 2016; Dilena et al., 2017; Flor-Hirsch et al., 2018; Kim et al., 2020; Melikishvili et al., 2020; Miao et al., 2020; Penkl et al., 2021). Here, SCN2A is linked to epilepsy.